One in two Europeans believe biotechnology will improve quality of life

52% of those polled in the latest Eurobarometer survey on biotechnology, published today, indicated a belief that biotechnology will improve their quality of life. The Eurobarometer "Europeans and biotechnology in 2005" shows that most Europeans are in favour of medical (red) applications of biotechnology when there are clear benefits for human health; and industrial (white) applications, but they are still mostly sceptical about agricultural (green) biotech, and will continue to be so unless new crops and products are seen to have consumer benefits. Confidence has increased in the European Union's regulation of biotechnology but there is no evidence that this has influenced the public's reported purchasing intentions, especially for GM foods. Overall, optimism about biotechnology's contribution to improving society has grown significantly since 1999. There is also support for research using stem cells, provided this is tightly regulated. This survey is the latest in a series of regular surveys on attitudes to biotechnology undertaken since 1991.

The survey examines issues such as:

  • Optimism about the contribution of technology , including biotechnology, to our way of life. Here, the survey shows that optimism about biotechnology has increased since 1999, after a period of decline (52% say it will improve their life).
  • The development of nanotechnology, pharmacogenetics (analysing a person’s genetic code in order to create drugs which are tailored to him/her and are therefore more effective) and gene therapy, all three of which are generally perceived as useful to society and morally acceptable.
  • GM food , where a majority of Europeans (58%) think it should not be encouraged.
  • Industrial (white) biotechnologies, such as bio-fuels, bio-plastics (plastics manufactures from crop plants) and biopharming (the use of genetically modified plants in the production of medicines and pharmaceutical products) for pharmaceuticals, which are widely supported.
  • Stem cell research , where there is considerable support across Europe, if tightly regulated. There is approval for use of both stem cells derived from umbilical cords (65%) and embryonic stem cells (59%), with 26% of people saying they do not approve of embryonic stem cell research at all or only under very special circumstances.
  • Use of personal genetic data , with 58% of participants indicating they would allow their genetic data to be banked for research purposes, though there are differing levels of support for genetic data banks across the EU.
  • Trust in actors involved in biotechnology , which shows growing levels of trust in university and industry scientists (73% and 64%). The EU is seen as more trustworthy than national governments on issues of regulating biotechnology (74% compared with 68%).
  • Comparison of attitudes with US and Canada , dispelling claims that European public opinion is more technology-adverse than its transatlantic partners. Close analysis of the data shows that it is inaccurate to ascribe certain attitudes to biotechnology by age group, or gender.

This survey is the latest in a series of such Eurobarometers on biotechnology conducted in 1991, 1993, 1996, 1999, 2002 and 2005. The sixth Eurobarometer on Biotechnology 2005 is based on a representative sample of 25 000 respondents, approximately 1 000 in each EU Member State.

The experts who undertook this survey will present the findings at a workshop on 22 June. To download the full report and read the executive summary, please visit: www.ec.europa.eu/research/press/2006/pr1906en.cfm

Most Popular Now

Smartphone Photos can be Used to Detect …

A picture of a person's inner eyelid taken with a standard smartphone camera can be used to screen for anemia, according to a new study published this week in the...

Exscientia Accelerates COVID-19 Drug Dis…

Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the COVID-19 Therapeutics Accelerator. This is to expedite the optimisation of...

Collaboration Between AbbVie, Biogen an…

The access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE:...

It's Going to be Quite a Handover…

Health and social care secretary Matt Hancock has been abruptly replaced by Sajid Javid. The Highland Marketing advisory board consider the huge agenda he is now facing, and what it...

Philips and Cognizant Collaborate to Int…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Cognizant (Nasdaq: CTSH), a world-leading professional services firm, announced a new collaboration to develop end-to-end digital health...

Philips Accelerates Stroke Diagnosis and…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced a strategic partnership agreement with NICO.LAB, a MedTech stroke care company. Together with the recently expanded stroke...

Fujitsu Announces Support of AWS for Hea…

Fujitsu in the UK has announced its support of the AWS for Health initiative from Amazon Web Services (AWS) by bringing Epic in the Cloud to NHS trusts and UK...

Ethics and Governance of Artificial Inte…

Artificial Intelligence (AI) refers to the ability of algorithms encoded in technology to learn from data so that they can perform automated tasks without every step in the process having...

Open Call HORIZON-HLTH-2021-TOOL-06-01: …

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 "Unlocking the full potential of new tools, technologies and digital...

New High-Tech Portal Launched to Speed H…

Researchers at the University of Maryland School of Medicine (UMSOM) launched a new online tool that could more quickly advance medical discoveries to reverse progressive hearing loss. The tool enables...

Artificial Intelligence Models to Analyz…

Artificial intelligence tools and deep learning models are a powerful tool in cancer treatment. They can be used to analyze digital images of tumor biopsy samples, helping physicians quickly classify...

Policy, Progress, Pace: Is the NHS Final…

Opinion Article by Lynette Ousby, UK Managing Director, Alcidion. There is a new energy emerging that might shake up the health tech market, and long-embedded challenges around siloed data and technologies. Political...